Presentation is loading. Please wait.

Presentation is loading. Please wait.

New Trends in Managing the Prostate Cancer Patient

Similar presentations


Presentation on theme: "New Trends in Managing the Prostate Cancer Patient"— Presentation transcript:

1 New Trends in Managing the Prostate Cancer Patient
Richard Berges  European Urology Supplements  Volume 7, Issue 13, Pages (December 2008) DOI: /j.eursup Copyright © Terms and Conditions

2 Fig. 1 Box and whiskers plot of total testosterone values after bilateral orchidectomy (n=35) [12]. Reprinted with permission from Urology[12]. European Urology Supplements 2008 7, DOI: ( /j.eursup ) Copyright © Terms and Conditions

3 Fig. 2 With the different Eligard depot formulations (Eligard 1-mo, Eligard 3-mo, and Eligard 6-mo), castrate testosterone levels were achieved in 88–98% of patients, with maximal testosterone values varying from 27ng/dl to 35ng/dl [11,33,34] (Data on file: clinical study reports Eligard 7.5, 22.5 and 45mg). European Urology Supplements 2008 7, DOI: ( /j.eursup ) Copyright © Terms and Conditions

4 Fig. 3 Preferences for Eligard 1-mo, Eligard 3-mo, or Eligard 6-mo injections for hormone therapy differ among patient age groups [39]. European Urology Supplements 2008 7, DOI: ( /j.eursup ) Copyright © Terms and Conditions


Download ppt "New Trends in Managing the Prostate Cancer Patient"

Similar presentations


Ads by Google